Point-of-Care Diagnostics World Congress 2013 Agenda

Registration

Microfluidics-enable Molecular Diagnostics for Infectious Diseases
Holger Becker, Chief Scientific Officer, Microfluidic ChipShop GmbH, Germany

Microfluidics has become one of the key enabling technologies for the product development in molecular diagnostics. We present building blocks for molecular diagnostic cartridges and demonstrate application cases such as sepsis, pneumonia or urinary tract infections.

Coffee and Networking in Exhibiton Hall

Rapid Isolation and Detection of Cancer Related cfc-DNA/RNA Biomarkers Directly from Patient Blood Samples
Michael Heller, Professor, Dept Bioengineering, University of California-San Diego, United States of America

A dielectrophoretic (DEP) device was used to isolate ccf-DNA directly from blood samples from 15 chronic lymphocytic leukemia (CLL) patients and 3 healthy individuals. The complete process, 25ul blood sample to ccf-DNA for PCR, was completed in less than 10 minutes. The PCR and DNA sequencing results were comparable to results obtained using much more time consuming and laborious “Gold Standard” processes.

Lunch and Networking in Exhibition Hall

Poster Viewing Session

Novel Electrochemical Platforms as Promising Alternatives for Cancer Biomarkers and Infectious Bacteria Determination
Susana Campuzano, Post Doctoral Scholar, Universidad Complutense de Madrid, Spain

In this presentation novel sensing platforms developed for the determination of clinically relevant biomarkers considered as sensitive and selective reporters of infection and cancer will be summarized and discussed. The great analytical performance exhibited by these methodologies will pave the way for the development of convenient point-of-care (POC) devices to allow diagnostic/prognosis and therapeutic action in primary health care.

Molecular Detection with Plasmonic Structures
Steve Blair, Professor, University of Utah, United States of America

Plasmonic structures facilitate the interaction between light and biomolecules and may serve as a key enabling factor in the next generation of single-molecule diagnostic tools. One modality of enhancement lies in increased signal-to-background ratio in fluorescence detection, which will be the focus of the presentation.

Coffee and Networking in Exhibiton Hall

Development of Biostabilization Methods in all Ambient Workflow for Point-of-Care Molecular Diagnostics MDx
Rolf Muller, Founder, President and Chief Scientific Officer, Biomatrica, United States of America

There is an increasing need for the development of technologies for handling human specimens in an all ambient workflow at point-of-care, laboratory and field settings without sacrificing the quality of molecular analytes contained in patient samples. Biomatrica has developed sample biostabilization technology that eliminates the need for cold chain transport and storage of specimens, resulting in significant cost savings for the diagnostic laboratory workflow. Data will be presented to demonstrate that such biostabilized nucleic acid samples retain near-native quality and quantity compared to fresh samples and can also be used for molecular diagnostics based on comprehensive genomic data generated by next-gen sequencing platforms. Biomatrica’s biostabilization based complete ambient diagnostic workflow holds great promise for molecular diagnostic applications in a point of care setting.

ALK, ROS1 and RET Fusion Detection in Lung Cancer
Maruja Lira, Senior Scientist, Pfizer Inc, United States of America

~7% of non-small cell lung carcinomas (NSCLC) harbor oncogenic fusions involving ALK, ROS1 and RET. We developed and validated a single-tube multiplex assay to detect the three fusions. Our test shows promise as a more practical and cost-effective screening modality for detection of rare but targetable fusions in lung cancer.

Reception and Roundtable Discussions in Exhibition Hall

End of Day One

Coffee and Networking in Exhibiton Hall

Automated Sequencing Analysis Tool for Infectious Disease Diagnostics
Robert Yamamoto, Founder, Zova Systems, United States of America

The RAPID-MG sequencing analysis tool to quickly, automatically identify microbial species from Next Gen Sequencing data as well as infectious disease diagnostic workflows including microbial DNA enrichment techniques will be presented.

Molecular Cross Talks FoxP3 with HDAC7&9 and FoxP3-HAT (p300) Underlying to Immune Suppression Activities of FoxP3 in Leprosy Patients
Raza Ali Naqvi, Post-doc, AIIMS, New Delhi, India

The present report envisages two important phenomenons from leprosy orifice 1) how does FoxP3 behave like potent transcription repression, 2) how does the expression of FoxP3 foster competitive fitness to T regs.

Lunch and Networking in Exhibition Hall

Poster Viewing Session

Esoteric Diagnostics in China: A Case Review of Building up the First and Largest Esoteric Laboratory Network in China
Shiang Huang, Chief Executive Officer, Kindstar Global, China

Kindstar Global Diagnostics, Inc. is the first and largest esoteric reference laboratory network in China and currently providing over 1600 tests to 3300 hospitals including 1100 large/leading hospitals(representing 75% of this type of hospital in China)in all 31 provinces with 600 cities/towns in China. Kindstar Global has three lab facilities in Beijing, Shanghai and Wuhan with over 1800 employees now. Kindstar has been invested by KPCB, Baird and so on with over $35M capital, and formed an exclusive strategic partnership with Mayo Clinic in China.

Close of Conference